PIERRE FABRE MEDICAMENT

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Nicotine Patch Safety Study

Phase 2

Completed

Conditions: Smokers

Interventions: Drug: V0116 transdermal patch
Drug: Nicotine transdermal patch

First Posted Date: 2012-08-01

Last Posted Date: 2012-12-11

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 160

Registration Number: NCT01655082

Effect of F2695 on Functional Recovery After Ischemic Stroke

Phase 3

Completed

Conditions: Ischemic Stroke

Interventions: Drug: placebo
Drug: F2695

First Posted Date: 2012-07-12

Last Posted Date: 2015-04-01

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 532

Registration Number: NCT01639014

Locations: 🇧🇪
Clinique Saint-Joseph, Liege, Belgium
🇧🇪
Regional Ziekenhuis Sint-Trudo, Sint-Truiden, Belgium
🇨🇿
Litomyšlská Nemocnice, a.s., Litomyšl, Czech Republic

and more 84 locations

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia (BPH)

Interventions: Drug: Permixon® 160 mg
Drug: Tamsulosine Arrow LP
Drug: Placebo matching Permixon® 160 mg
Drug: Placebo matching Tamsulosine Arrow LP

First Posted Date: 2012-05-24

Last Posted Date: 2014-01-15

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 206

Registration Number: NCT01604811

JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin

Phase 2

Completed

Conditions: Bladder Transitional Cell Carcinoma Stage IV

Interventions: Drug: Vinflunine, Gemcitabine
Drug: Vinflunine, Carboplatin

First Posted Date: 2012-05-15

Last Posted Date: 2015-12-08

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 69

Registration Number: NCT01599013

Locations: 🇫🇷
Pierre Fabre Research Institute, Boulogne, France

Effect of V0251 in Acute Vertigo

Phase 2

Completed

Conditions: Acute Vertigo

Interventions: Drug: V0251
Drug: placebo

First Posted Date: 2012-04-24

Last Posted Date: 2014-10-30

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 132

Registration Number: NCT01583738

Locations: 🇭🇺
Pécsi Tudományegyetem Általános Orvostudományi Kar, Pecs, Hungary
🇪🇸
Hospital Universitario La Fe, Valencia, Spain
🇭🇺
Petz Aladár Megyei Oktató Kórház, Gyor, Hungary

and more 36 locations

Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations

Phase 1

Completed

Conditions: Healthy Smokers

Interventions: Drug: Niquitin® Fresh Mint 4 mg
Drug: V0018 - B mg
Drug: V0474 - C mg
Drug: V0474 - B mg
Drug: V0474 - A mg

First Posted Date: 2012-04-10

Last Posted Date: 2012-07-10

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 13

Registration Number: NCT01574898

Locations: 🇫🇷
Eurofins Optimed, Gieres, France

Acute Sore Throat Pain Study

Phase 2

Completed

Conditions: Acute Sore Throat Pain

Interventions: Drug: Placebo
Drug: Ibuprofen 15 mg
Drug: Ibuprofen 25 mg
Drug: Ibuprofen 35 mg
Drug: Strefen

First Posted Date: 2012-02-17

Last Posted Date: 2012-11-12

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 186

Registration Number: NCT01535079

Locations: 🇫🇷
Eurofins Optimed, Gières, France
🇫🇷
Eurofins Optimed Lyon, Pierre Bénite, France

Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis

Not Applicable

Withdrawn

Conditions: Knee Osteoarthritis

Interventions: Device: Chondroitin sulfate and sodium hyaluronate
Drug: Hyaluronan

First Posted Date: 2011-11-10

Last Posted Date: 2013-02-21

Lead Sponsor: Pierre Fabre Medicament

Registration Number: NCT01469507

Efficacy Emollient on Xerosis in Children With Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: V0034CR01B
Drug: Vehicle cream
Drug: desonide 0.1% cream
Other: Foaming gel

First Posted Date: 2011-11-08

Last Posted Date: 2013-02-21

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 251

Registration Number: NCT01467362

Locations: 🇱🇹
Lithuania, Vilnius, Lithuania
🇵🇱
Poland, Żyrardów, Poland
🇪🇪
Estonia, Tartu, Estonia

and more 2 locations

Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema

Phase 3

Completed

Conditions: Chronic Venous Insufficiency (CVI)

Interventions: Device: V0322 BC

First Posted Date: 2011-07-26

Last Posted Date: 2016-11-10

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 92

Registration Number: NCT01402921

Locations: 🇫🇷
Centre Hospitalo-Universitaire Grenoble, Grenoble, Isère, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy